Chinese Medicinal Formulas As Retention Enemas in Patients with Radiation Proctitis: A Multicenter Retrospective Survey
W. He,X. Liu,O. Jiang,K. Lei,Q. Zhou,L. Wang,X. Chen,R. Ding,Q. Wen
DOI: https://doi.org/10.1016/j.ijrobp.2017.06.1076
2017-01-01
Abstract:This study aimed to assess whether Chinese medicinal formulas as retention enemas could effectively treat radiation proctitis following radiotherapy in patients with pelvic malignant disease. This study was an open-label, retrospective, multicenter study of patients with radiation proctitis treated with Chinese medicinal formulas as retention enemas. The diagnosis adhered to the Diagnostic Criteria for Radiation Proctitis (GBZ 111-2002). The degree of radiation proctitis was classified into a graded system devised by Radiation Therapy Oncology Group (RTOG). Retrospective data were collected from patients’ medical records in 5 hospitals for the 2011-2016 period. Patient follow-up was conducted via outpatient service and telephone. The patients were divided into 3 treatments based on the ingredient present in the Chinese medicinal formulas, as follows: Treatment A (intestinal mucosa protector, symptomatic treatment), Treatment B (symptomatic treatment), and Treatment C (Chinese Medicinal Formulae, symptomatic treatment). Data were analyzed using SPSS ver. 20.0, and quantitative data were summarized using mean±standard deviation. Comparison of treatments was conducted using analysis of variance (one-way ANOVA). Qualitative data were analyzed using the chi-square test or Fisher’s exact probabilities test. P©,0.05 was considered statistically significant. A total of 1463 patients who received pelvic radiotherapy were reviewed in our study. The incidence rate of radiation proctitis was 10.1% (n=148), consisting of acute radiation proctitis (ARP) and chronic radiation proctitis (CRP) at 5.6% (n=83) and 5.1% (n=75), respectively. The retention enema was used in 105 cases of patients with radiation proctitis, including ARP (n=49) and CRP (n=56). The patients mostly experienced RTOG acute grade 1 (n=34) or 2 (n=15), or chronic grade 1 (n=35) to 2 (n=21) toxicities. Most patients suffered from diarrhea, bleeding, pain, and tenesmus. The symptoms were partially or completely improved in 85.7% of patients with ARP after therapy. The response rates of ARP administered with Treatments A, B, and C, were 70.6%, 90.5%, and 100%, respectively.Approximately 69.6% of patients with CRP exhibited partial to good response after retention enema. The response rates of CRP administered with Treatments A, B, and C, were 46.1%, 66.6%, and 84%, respectively. The response of grade-1 CRP to Treatment C (93.3%) was better than its response to Treatments A (50%) and B (70%). Kangfuxin (n=34) and Xilei powder (n=33) were the most common intestinal mucosa protective agent and Chinese Medicinal Formulae in the treatment of radiation proctitis in Groups A and C, respectively. Kangfuxin and Xilei powder in Chinese medicinal formulas used as retention enemas may significantly improve the clinical symptoms of patients with radiation proctitis. In particular, Xilei powder for grade-1 CRP exhibited an obvious effect.